{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T18:11:11Z","timestamp":1788459071965,"version":"build-2803163510"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T00:00:00Z","timestamp":1759104000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T00:00:00Z","timestamp":1759104000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["R01DK120598"],"award-info":[{"award-number":["R01DK120598"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J GEN INTERN MED"],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Weight gain after starting antihypertensive medications is a frequent concern for patients, but there is limited data on expected weight change after initiation of these medications. A comparative effectiveness trial to evaluate this outcome would not be feasible.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To estimate and compare average weight change under initiating and adhering to commonly prescribed, first-line antihypertensive medications as monotherapy by emulating a target trial.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Retrospective observational cohort study over 24\u00a0months of follow-up using electronic health records (EHR).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>141,260 patients prescribed one of seven antihypertensives between 2010 and 2019 across 8 US health systems.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main Outcome and Measures<\/jats:title>\n                    <jats:p>We examined mean weight change associated with initiation of and adherence to amlodipine, atenolol, hydrochlorothiazide, losartan, metoprolol, or propranolol, relative to lisinopril, at 6, 12, and 24\u00a0months after initiation. To adjust for baseline confounding and informative outcome measurement, we used inverse probability weighting with repeated outcome marginal structural models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Key Results<\/jats:title>\n                    <jats:p>After baseline and time-varying covariate adjustment, initiation of and adherence to lisinopril were associated with mean weight loss at 6\u00a0months (\u2212\u20090.69\u00a0kg, 95% CI\u2009\u2212\u20090.92,\u2009\u2212\u20090.47), 12\u00a0months (\u2212\u20090.58\u00a0kg, 95% CI\u2009\u2212\u20091.05,\u2009\u2212\u20090.30), and 24\u00a0months (\u2212\u20091.121\u00a0kg, 95% CI\u2009\u2212\u20092.013,\u2009\u2212\u20090.46). Compared to lisinopril, the estimated 6-month weight change was higher for patients prescribed hydrochlorothiazide (0.68\u00a0kg, 95% CI 0.31, 1.04), losartan (0.54\u00a0kg, 95% CI 0.17, 0.93), metoprolol (1.38\u00a0kg, 95% CI 0.95, 1.76), and propranolol (1.03\u00a0kg, 95% CI 0.346, 1.62). At 12\u00a0months, metoprolol (1.74\u00a0kg, 95% CI 1.03, 2.41) and propranolol (1.72\u00a0kg, 95% CI 0.06, 3.235) continued to show higher weight change compared to lisinopril.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>We observed small differences in weight change across antihypertensive medications, with lisinopril leading to weight loss and metoprolol and propranolol to modest weight gain. Clinicians should consider potential weight gain when selecting antihypertensive medications.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11606-025-09787-x","type":"journal-article","created":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T19:28:03Z","timestamp":1759174083000},"page":"1097-1106","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Emulation of a Target Trial of Antihypertensive Medications on Weight Change"],"prefix":"10.1007","volume":"41","author":[{"given":"Pi-I D.","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheryl L.","family":"Rifas-Shiman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Petimar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew F.","family":"Daley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Janicke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William J.","family":"Heerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. Charles","family":"Bailey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Maeztu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina H.","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica G.","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7660-9064","authenticated-orcid":false,"given":"Jason P.","family":"Block","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,29]]},"reference":[{"issue":"4","key":"9787_CR1","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/s41581-019-0244-2","volume":"16","author":"KT Mills","year":"2020","unstructured":"Mills KT, Stefanescu A, He J. The global epidemiology of hypertension. Nat Rev Nephrol. 2020;16(4):223-237. https:\/\/doi.org\/10.1038\/s41581-019-0244-2","journal-title":"Nat Rev Nephrol."},{"issue":"6","key":"9787_CR2","doi-asserted-by":"publisher","first-page":"e13","DOI":"10.1161\/HYP.0000000000000065","volume":"71","author":"P Whelton","year":"2017","unstructured":"Whelton P. 2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2017;71(6):e13-e115. https:\/\/doi.org\/10.1161\/HYP.0000000000000065","journal-title":"Hypertension."},{"key":"9787_CR3","doi-asserted-by":"crossref","unstructured":"Sekkarie A, Fang, J., Hayes, D., Loustalot, F. Prevalence of Self-Reported Hypertension and Antihypertensive Medication Use Among Adults \u2014 United States, 2017\u20132021. Centers for Disease Control and Prevention; 2024:191\u2013198.","DOI":"10.15585\/mmwr.mm7309a1"},{"issue":"10","key":"9787_CR4","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1111\/jch.13364","volume":"20","author":"MD Ritchey","year":"2018","unstructured":"Ritchey MD, Gillespie C, Wozniak G, et al. Potential need for expanded pharmacologic treatment and lifestyle modification services under the 2017 ACC\/AHA Hypertension Guideline. J Clin Hypertens (Greenwich). 2018;20(10):1377-1391. https:\/\/doi.org\/10.1111\/jch.13364","journal-title":"J Clin Hypertens (Greenwich)."},{"issue":"17","key":"9787_CR5","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1212\/WNL.0b013e3182535d20","volume":"78","author":"SD Silberstein","year":"2012","unstructured":"Silberstein SD, Holland S, Freitag F, et al. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology. 2012;78(17):1337-1345. https:\/\/doi.org\/10.1212\/WNL.0b013e3182535d20","journal-title":"Neurology."},{"issue":"1","key":"9787_CR6","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s10194-023-01594-1","volume":"24","author":"C Lampl","year":"2023","unstructured":"Lampl C, MaassenVanDenBrink A, Deligianni CI, et al. The comparative effectiveness of migraine preventive drugs: a systematic review and network meta-analysis. J Headache Pain. 2023;24(1):56. https:\/\/doi.org\/10.1186\/s10194-023-01594-1","journal-title":"J Headache Pain."},{"issue":"2","key":"9787_CR7","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1161\/01.hyp.37.2.250","volume":"37","author":"AM Sharma","year":"2001","unstructured":"Sharma AM, Pischon T, Hardt S, Kunz I, Luft FC. Hypothesis: Beta-adrenergic receptor blockers and weight gain: A systematic analysis. Hypertension. 2001;37(2):250-254. https:\/\/doi.org\/10.1161\/01.hyp.37.2.250","journal-title":"Hypertension."},{"key":"9787_CR8","doi-asserted-by":"publisher","first-page":"427","DOI":"10.2147\/DMSO.S171365","volume":"11","author":"S Wharton","year":"2018","unstructured":"Wharton S, Raiber L, Serodio KJ, Lee J, Christensen RA. Medications that cause weight gain and alternatives in Canada: a narrative review. Diabetes Metab Syndr Obes. 2018;11:427-438. https:\/\/doi.org\/10.2147\/DMSO.S171365","journal-title":"Diabetes Metab Syndr Obes."},{"issue":"11","key":"9787_CR9","first-page":"780","volume":"65","author":"KH Saunders","year":"2016","unstructured":"Saunders KH, Igel LI, Shukla AP, Aronne LJ. Drug-induced weight gain: Rethinking our choices. J Fam Pract. 2016;65(11):780-788.","journal-title":"J Fam Pract."},{"issue":"4","key":"9787_CR10","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1046\/j.1467-789x.2001.00044.x","volume":"2","author":"T Pischon","year":"2001","unstructured":"Pischon T, Sharma AM. Use of beta-blockers in obesity hypertension: potential role of weight gain. Obes Rev. 2001;2(4):275-280. https:\/\/doi.org\/10.1046\/j.1467-789x.2001.00044.x","journal-title":"Obes Rev."},{"issue":"1","key":"9787_CR11","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1185\/030079904x20277","volume":"21","author":"DA Anichkov","year":"2005","unstructured":"Anichkov DA, Shostak NA, Schastnaya OV. Comparison of rilmenidine and lisinopril on ambulatory blood pressure and plasma lipid and glucose levels in hypertensive women with metabolic syndrome. Curr Med Res Opin. 2005;21(1):113-119. https:\/\/doi.org\/10.1185\/030079904x20277","journal-title":"Curr Med Res Opin."},{"key":"9787_CR12","doi-asserted-by":"publisher","unstructured":"Reisin E, Weir MR, Falkner B, Hutchinson HG, Analone ML, TROPHY Study Group. Lisinopril versus hydrochlorothiazide in obese hypertensive patients: a multicenter placebo-controlled trial. Treatment in Obese Patients With Hypertension (TROPHY) Study Group -. Hypertension. 1997;30. https:\/\/doi.org\/10.1161\/01.HYP.30.1.140","DOI":"10.1161\/01.HYP.30.1.140"},{"issue":"4","key":"9787_CR13","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1038\/hr.2010.6","volume":"33","author":"A Masajtis-Zagajewska","year":"2010","unstructured":"Masajtis-Zagajewska A, Majer J, Nowicki M. Effect of moxonidine and amlodipine on serum YKL-40, plasma lipids and insulin sensitivity in insulin-resistant hypertensive patients-a randomized, crossover trial. Hypertension Research. 2010;33(4):348-353. https:\/\/doi.org\/10.1038\/hr.2010.6.","journal-title":"Hypertension Research."},{"issue":"7","key":"9787_CR14","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1093\/ajh\/2.7.537","volume":"2","author":"SG Chrysant","year":"1989","unstructured":"Chrysant SG, Chrysant C, Trus J, Hitchcock A. Antihypertensive effectiveness of amlodipine in combination with hydrochlorothiazide. Am J Hypertens. 1989;2(7):537-541. https:\/\/doi.org\/10.1093\/ajh\/2.7.537","journal-title":"Am J Hypertens."},{"issue":"8","key":"9787_CR15","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1093\/aje\/kwv254","volume":"183","author":"MA Hern\u00e1n","year":"2016","unstructured":"Hern\u00e1n MA, Robins JM. Using Big Data to Emulate a Target Trial When a Randomized Trial Is Not Available. Am J Epidemiol. 2016;183(8):758-764. https:\/\/doi.org\/10.1093\/aje\/kwv254","journal-title":"Am J Epidemiol."},{"issue":"6","key":"9787_CR16","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/s10654-017-0287-2","volume":"32","author":"X Garc\u00eda-Alb\u00e9niz","year":"2017","unstructured":"Garc\u00eda-Alb\u00e9niz X, Hsu J, Hern\u00e1n MA. The value of explicitly emulating a target trial when using real world evidence: an application to colorectal cancer screening. Eur J Epidemiol. 2017;32(6):495-500. https:\/\/doi.org\/10.1007\/s10654-017-0287-2","journal-title":"Eur J Epidemiol."},{"issue":"11","key":"9787_CR17","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1002\/jhm.13171","volume":"18","author":"M Colacci","year":"2023","unstructured":"Colacci M, Fralick M. Methodological progress note: Utilizing inpatient data sources to minimize common biases when emulating target trials. J Hosp Med. 2023;18(11):1017-1020. https:\/\/doi.org\/10.1002\/jhm.13171","journal-title":"J Hosp Med."},{"issue":"21","key":"9787_CR18","doi-asserted-by":"publisher","first-page":"1975","DOI":"10.1056\/NEJMp2407586","volume":"391","author":"RA Hubbard","year":"2024","unstructured":"Hubbard RA, Gatsonis CA, Hogan JW, Hunter DJ, Normand SLT, Troxel AB. \u201cTarget Trial Emulation\u201d for Observational Studies - Potential and Pitfalls. N Engl J Med. 2024;391(21):1975-1977. https:\/\/doi.org\/10.1056\/NEJMp2407586","journal-title":"N Engl J Med."},{"issue":"3","key":"9787_CR19","doi-asserted-by":"publisher","first-page":"402","DOI":"10.7326\/ANNALS-24-01871","volume":"178","author":"MA Hern\u00e1n","year":"2025","unstructured":"Hern\u00e1n MA, Dahabreh IJ, Dickerman BA, Swanson SA. The Target Trial Framework for Causal Inference From Observational Data: Why and When Is It Helpful? Ann Intern Med. 2025;178(3):402-407. https:\/\/doi.org\/10.7326\/ANNALS-24-01871","journal-title":"Ann Intern Med."},{"issue":"9","key":"9787_CR20","doi-asserted-by":"publisher","first-page":"e032197","DOI":"10.1161\/JAHA.123.032197","volume":"13","author":"PD Lin","year":"2024","unstructured":"Lin PD, Rifas\u2010Shiman S, Merriman J, et al. Trends of Antihypertensive Prescription Among US Adults From 2010 to 2019 and Changes Following Treatment Guidelines: Analysis of Multicenter Electronic Health Records. Journal of the American Heart Association. 2024;13(9):e032197. https:\/\/doi.org\/10.1161\/JAHA.123.032197","journal-title":"Journal of the American Heart Association."},{"key":"9787_CR21","doi-asserted-by":"publisher","unstructured":"Petimar J, Young JG, Yu H, et al. Medication-Induced Weight Change Across Common Antidepressant Treatments\u202f: A Target Trial Emulation Study. Ann Intern Med. Published online July 2, 2024. https:\/\/doi.org\/10.7326\/M23-2742","DOI":"10.7326\/M23-2742"},{"issue":"3","key":"9787_CR22","doi-asserted-by":"publisher","first-page":"204","DOI":"10.18043\/ncm.75.3.204","volume":"75","author":"RM Califf","year":"2014","unstructured":"Califf RM. The Patient-Centered Outcomes Research Network: a national infrastructure for comparative effectiveness research. N C Med J. 2014;75(3):204-210. https:\/\/doi.org\/10.18043\/ncm.75.3.204","journal-title":"N C Med J."},{"key":"9787_CR23","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.jclinepi.2020.09.036","volume":"129","author":"CB Forrest","year":"2021","unstructured":"Forrest CB, McTigue KM, Hernandez AF, et al. PCORnet\u00ae 2020: current state, accomplishments, and future directions. J Clin Epidemiol. 2021;129:60-67. https:\/\/doi.org\/10.1016\/j.jclinepi.2020.09.036","journal-title":"J Clin Epidemiol."},{"key":"9787_CR24","doi-asserted-by":"crossref","unstructured":"Wanis KN, Sarvet AL, Wen L, et al. Grace periods in comparative effectiveness studies of sustained treatments. Journal of the Royal Statistical Society Series A: Statistics in Society. Published online January 2024:qnae002.","DOI":"10.1093\/jrsssa\/qnae002"},{"issue":"4","key":"9787_CR25","doi-asserted-by":"publisher","first-page":"ooac089","DOI":"10.1093\/jamiaopen\/ooac089","volume":"5","author":"PID Lin","year":"2022","unstructured":"Lin PID, Rifas-Shiman SL, Aris IM, et al. Cleaning of anthropometric data from PCORnet electronic health records using automated algorithms. JAMIA Open. 2022;5(4):ooac089. https:\/\/doi.org\/10.1093\/jamiaopen\/ooac089","journal-title":"JAMIA Open."},{"issue":"6","key":"9787_CR26","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1093\/jamia\/ocx037","volume":"24","author":"C Daymont","year":"2017","unstructured":"Daymont C, Ross ME, Russell Localio A, Fiks AG, Wasserman RC, Grundmeier RW. Automated identification of implausible values in growth data from pediatric electronic health records. J Am Med Inform Assoc. 2017;24(6):1080-1087. https:\/\/doi.org\/10.1093\/jamia\/ocx037","journal-title":"J Am Med Inform Assoc."},{"issue":"1","key":"9787_CR27","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1093\/jamia\/ocab250","volume":"29","author":"C Daymont","year":"2021","unstructured":"Daymont C, Ross ME, Localio AR, Fiks AG, Wasserman RC, Grundmeier RW. Corrigendum to: Automated identification of implausible values in growth data from pediatric electronic health records. J Am Med Inform Assoc. 2021;29(1):223. https:\/\/doi.org\/10.1093\/jamia\/ocab250","journal-title":"J Am Med Inform Assoc."},{"issue":"526","key":"9787_CR28","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1080\/01621459.2018.1469993","volume":"114","author":"JG Young","year":"2019","unstructured":"Young JG, Logan RW, Robins JM, Hern\u00e1n MA. Inverse probability weighted estimation of risk under representative interventions in observational studies. J Am Stat Assoc. 2019;114(526):938-947. https:\/\/doi.org\/10.1080\/01621459.2018.1469993","journal-title":"J Am Stat Assoc."},{"issue":"5","key":"9787_CR29","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1097\/00001648-200009000-00011","volume":"11","author":"JM Robins","year":"2000","unstructured":"Robins JM, Hern\u00e1n MA, Brumback B. Marginal structural models and causal inference in epidemiology. Epidemiology. 2000;11(5):550-560. https:\/\/doi.org\/10.1097\/00001648-200009000-00011","journal-title":"Epidemiology."},{"key":"9787_CR30","doi-asserted-by":"publisher","unstructured":"Toh S, Hern\u00e1n MA. Causal inference from longitudinal studies with baseline randomization. Int J Biostat. 2008;4(1):Article 22. https:\/\/doi.org\/10.2202\/1557-4679.1117","DOI":"10.2202\/1557-4679.1117"},{"issue":"1","key":"9787_CR31","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1186\/s13063-019-3577-z","volume":"20","author":"JG Young","year":"2019","unstructured":"Young JG, Vatsa R, Murray EJ, Hern\u00e1n MA. Interval-cohort designs and bias in the estimation of per-protocol effects: a simulation study. Trials. 2019;20(1):552. https:\/\/doi.org\/10.1186\/s13063-019-3577-z","journal-title":"Trials."},{"issue":"4","key":"9787_CR32","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.jclinepi.2007.11.008","volume":"61","author":"E von Elm","year":"2008","unstructured":"von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol. 2008;61(4):344-349. https:\/\/doi.org\/10.1016\/j.jclinepi.2007.11.008","journal-title":"J Clin Epidemiol."},{"issue":"2","key":"9787_CR33","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1038\/ki.1989.190","volume":"36","author":"JE Heeg","year":"1989","unstructured":"Heeg JE, de Jong PE, van der Hem GK, de Zeeuw D. Efficacy and variability of the antiproteinuric effect of ACE inhibition by lisinopril. Kidney Int. 1989;36(2):272-279. https:\/\/doi.org\/10.1038\/ki.1989.190","journal-title":"Kidney Int."},{"issue":"7","key":"9787_CR34","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1016\/j.amjmed.2006.10.017","volume":"120","author":"FH Messerli","year":"2007","unstructured":"Messerli FH, Bell DSH, Fonseca V, et al. Body weight changes with beta-blocker use: results from GEMINI. Am J Med. 2007;120(7):610-615. https:\/\/doi.org\/10.1016\/j.amjmed.2006.10.017","journal-title":"Am J Med."},{"issue":"5","key":"9787_CR35","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1111\/j.1368-5031.2006.00951.x","volume":"60","author":"AF Sanjuliani","year":"2006","unstructured":"Sanjuliani AF, de Abreu VG, Francischetti EA. Selective imidazoline agonist moxonidine in obese hypertensive patients. Int J Clin Pract. 2006;60(5):621-629. https:\/\/doi.org\/10.1111\/j.1368-5031.2006.00951.x","journal-title":"Int J Clin Pract."},{"issue":"Suppl 7","key":"9787_CR36","doi-asserted-by":"publisher","first-page":"S89","DOI":"10.1097\/00005344-198812007-00020","volume":"12","author":"AR Lorimer","year":"1988","unstructured":"Lorimer AR, Smedsrud T, Walker P, Tyler HM. Comparison of amlodipine and verapamil in the treatment of mild to moderate hypertension. J Cardiovasc Pharmacol. 1988;12 Suppl 7:S89-93. https:\/\/doi.org\/10.1097\/00005344-198812007-00020","journal-title":"J Cardiovasc Pharmacol."},{"key":"9787_CR37","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1097\/00005344-198704000-00002","volume":"9","author":"SL Swartz","year":"1987","unstructured":"Swartz SL. Endocrine and vascular responses in hypertensive patients to long-term treatment with diltiazem. J Cardiovasc Pharmacol. 1987;9:391-395. https:\/\/doi.org\/10.1097\/00005344-198704000-00002","journal-title":"J Cardiovasc Pharmacol."},{"issue":"3","key":"9787_CR38","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1111\/j.0954-6820.1966.tb02846.x","volume":"180","author":"J Bergstrom","year":"1966","unstructured":"Bergstrom J, Hultman E. The effect of thiazides, chlorthalidone and furosemide on muscle electrolytes and muscle glycogen in normal subjects. Acta Med Scand. 1966;180(3):363-376. https:\/\/doi.org\/10.1111\/j.0954-6820.1966.tb02846.x","journal-title":"Acta Med Scand."},{"issue":"2","key":"9787_CR39","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1177\/000331977702800209","volume":"28","author":"FA Finnerty","year":"1977","unstructured":"Finnerty FA, Maxwell MH, Lunn J, Moser M. Long-term effects of furosemide and hydrochlorothiazide in patients with essential hypertension a two-year comparison of efficacy and safety. Angiology. 1977;28(2):125-133. https:\/\/doi.org\/10.1177\/000331977702800209","journal-title":"Angiology."},{"issue":"2","key":"9787_CR40","doi-asserted-by":"publisher","first-page":"177","DOI":"10.5001\/omj.2012.39","volume":"27","author":"MS Kostapano","year":"2012","unstructured":"Kostapano MS, Katsiki N, Athyros VG, Karagiannis A, Mikhailidis DP. Effects of Losartan vs. Enalapril on the Markers of Metabolic Syndrome. Oman Med J. 2012;27(2):177. https:\/\/doi.org\/10.5001\/omj.2012.39","journal-title":"Oman Med J."},{"issue":"1","key":"9787_CR41","doi-asserted-by":"publisher","first-page":"27","DOI":"10.5001\/omj.2012.05","volume":"27","author":"ZA Al-Thanoon","year":"2012","unstructured":"Al-Thanoon ZA, Mahmood IH. Effects of Losartan vs. Enalapril on the Markers of Metabolic Syndrome. Oman Med J. 2012;27(1):27-30. https:\/\/doi.org\/10.5001\/omj.2012.05","journal-title":"Oman Med J."},{"issue":"4","key":"9787_CR42","doi-asserted-by":"publisher","first-page":"663","DOI":"10.2337\/diacare.25.4.663","volume":"25","author":"CA Houlihan","year":"2002","unstructured":"Houlihan CA, Allen TJ, Baxter AL, et al. A low-sodium diet potentiates the effects of losartan in type 2 diabetes. Diabetes Care. 2002;25(4):663-671. https:\/\/doi.org\/10.2337\/diacare.25.4.663","journal-title":"Diabetes Care."},{"issue":"2","key":"9787_CR43","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1002\/hep.510290203","volume":"29","author":"AW Schneider","year":"1999","unstructured":"Schneider AW, Kalk JF, Klein CP. Effect of losartan, an angiotensin II receptor antagonist, on portal pressure in cirrhosis. Hepatology. 1999;29(2):334-339. https:\/\/doi.org\/10.1002\/hep.510290203","journal-title":"Hepatology."},{"issue":"6","key":"9787_CR44","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1136\/jim-2016-000102","volume":"64","author":"A Srivastava","year":"2016","unstructured":"Srivastava A, Adams-Huet B, Vega GL, Toto RD. Effect of losartan and spironolactone on triglyceride-rich lipoproteins in diabetic nephropathy. J Investig Med. 2016;64(6):1102-1108. https:\/\/doi.org\/10.1136\/jim-2016-000102","journal-title":"J Investig Med."},{"key":"9787_CR45","doi-asserted-by":"publisher","unstructured":"Sekkarie A. Prevalence of Self-Reported Hypertension and Antihypertensive Medication Use Among Adults \u2014 United States, 2017\u20132021. MMWR Morb Mortal Wkly Rep. 2024;73. https:\/\/doi.org\/10.15585\/mmwr.mm7309a1","DOI":"10.15585\/mmwr.mm7309a1"},{"key":"9787_CR46","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/1471-2288-14-118","volume":"14","author":"ML Bell","year":"2014","unstructured":"Bell ML, Fiero M, Horton NJ, Hsu CH. Handling missing data in RCTs; a review of the top medical journals. BMC Med Res Methodol. 2014;14:118. https:\/\/doi.org\/10.1186\/1471-2288-14-118","journal-title":"BMC Med Res Methodol."},{"issue":"1","key":"9787_CR47","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1177\/1740774511420743","volume":"9","author":"MA Hern\u00e1n","year":"2012","unstructured":"Hern\u00e1n MA, Hern\u00e1ndez-D\u00edaz S. Beyond the intention-to-treat in comparative effectiveness research. Clin Trials. 2012;9(1):48-55. https:\/\/doi.org\/10.1177\/1740774511420743","journal-title":"Clin Trials."}],"container-title":["Journal of General Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11606-025-09787-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11606-025-09787-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11606-025-09787-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T16:25:27Z","timestamp":1774283127000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11606-025-09787-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,29]]},"references-count":47,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["9787"],"URL":"https:\/\/doi.org\/10.1007\/s11606-025-09787-x","relation":{},"ISSN":["0884-8734","1525-1497"],"issn-type":[{"value":"0884-8734","type":"print"},{"value":"1525-1497","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,29]]},"assertion":[{"value":"17 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations:"}},{"value":"This study was approved by the Institutional Review Board of Harvard Pilgrim Health Care under an expedited review because the data included was collected for purposes other than research. The data utilized included only a Limited Data Set.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval and Consent to Participate:"}},{"value":"The authors declare that they do not have a conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest:"}}]}}